NEW YORK, Feb. 06, 2025 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today reported financial results for its fiscal third quarter ended December 31, 2024.
Immunovant Reports Financial Results for the Quarter Ended December 31, 2024
Seeking Alpha / 2 hours from now 1 Views
Comments